Immune Thrombocytopenia (ITP) – Evidence‑Based Management Summary

Diagnostic Workup

• The American Society of Hematology (ASH) recommends testing all patients for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) to identify secondary causes of ITP. [1][2]
• Screening for Helicobacter pylori infection (urea breath test, stool antigen, or endoscopic biopsy) and providing eradication therapy when positive is advised. [3][4]
• Routine bone‑marrow examination is not required in patients with typical ITP, irrespective of age. [1][5]
• Additional investigations are only warranted when abnormalities extend beyond isolated thrombocytopenia (excluding isolated iron‑deficiency findings). [1][4]

First‑Line Therapy (Newly Diagnosed Adult ITP)

• For adults with platelet count < 30 × 10⁹/L, initiate a longer course of corticosteroids as first‑line therapy; prednisone 0.5–2 mg/kg/day or dexamethasone 40 mg/day for 4 days are equally acceptable. [6][3]1
• Longer corticosteroid courses are preferred over short courses or IVIg alone. [6][3]1
• Recent data show no clear superiority between prednisone and dexamethasone. 7
• Add a single dose of IVIg (1 g/kg) to corticosteroids when a rapid platelet rise is needed (e.g., active bleeding, urgent surgery). [6][3]8
• If corticosteroids are contraindicated, IVIg or anti‑D immunoglobulin (in Rh‑positive, non‑splenectomized patients) may be used. [6][3]1
• The 2019 ASH guideline recommends against combining rituximab with corticosteroids as initial therapy because of insufficient benefit. 7

Indications to Initiate Treatment

• Treat adults when platelet count is < 30 × 10⁹/L (or higher if symptomatic). [1][9]10
• Observation is appropriate for asymptomatic patients with platelet counts above this threshold. 6

Second‑Line Therapy (After Corticosteroid Failure)

General Decision Framework

• Choice of second‑line therapy depends on disease duration (< 12 months vs ≥ 12 months) and patient priorities (avoidance of long‑term medication, surgery, or desire for durable response). 11

ITP Duration < 12 Months

• Thrombopoietin‑receptor agonists (TPO‑RAs) (romiplostim or eltrombopag) are the primary recommendation over rituximab, offering greater durability of response with ongoing use. 11
• Delay splenectomy during the first year because spontaneous remission remains possible. [6][9]12
• Rituximab may be considered for patients who cannot afford TPO‑RAs or who strongly prefer to avoid long‑term medication. 11

ITP Duration ≥ 12 Months

• Patients prioritizing avoidance of long‑term medication: rituximab is preferred over splenectomy despite lower durability, due to surgical risks of asplenia. 11
• Patients prioritizing avoidance of surgery: TPO‑RAs are preferred over rituximab because of superior durability. 11
• Patients prioritizing durable response: either splenectomy or a TPO‑RA is acceptable; selection hinges on willingness for surgery versus chronic medication. 11

Specific Second‑Line Recommendations (ASH)

• Conditional: Rituximab may be considered for bleeding‑risk patients who have failed one prior line of therapy. [6][3]9
• Conditional: TPO‑RAs may be used earlier (after corticosteroids/IVIg) in bleeding‑risk patients who have not undergone splenectomy. [6][9]

Special Populations

Pregnancy

• Treat pregnant patients who require intervention with corticosteroids or IVIg. [3][1]8
• Mode of delivery should be determined by obstetric indications, not platelet count alone. [3][1]2

Children and Adolescents

• Splenectomy is recommended for chronic/persistent ITP with significant bleeding unresponsive to corticosteroids, IVIg, and anti‑D. [6][1]9
• Delay splenectomy for ≥ 12 months unless disease is severe and refractory to other measures. [6][1][9][12]
• High‑dose dexamethasone may be considered for ongoing bleeding despite standard therapies or as an alternative to splenectomy. [6][5]

Secondary ITP

• HIV‑associated ITP: Treat underlying HIV with antiretroviral therapy first (Grade 1A). If ITP therapy is needed, use corticosteroids, IVIg, or anti‑D. [3][4]8
• HCV‑associated ITP: Consider antiviral therapy (monitor platelets; interferon may worsen thrombocytopenia). If ITP treatment is required, IVIg is the preferred initial agent. [3][2]8
• H. pylori‑associated ITP: Provide eradication therapy to all patients with confirmed infection (Grade 1B). [3][4]8

Post‑Splenectomy Management

• Do not treat asymptomatic patients after splenectomy who have platelet counts > 30 × 10⁹/L. [6][3][5][8]
• For relapse after splenectomy, TPO‑RAs are strongly recommended. [6][3]9

Critical Pitfalls & Ongoing Considerations

• Avoid routine upfront combination of rituximab with corticosteroids—evidence of benefit is insufficient. 7
• Do not rush to splenectomy within the first year; spontaneous remission remains possible. [6][11]
• Bone‑marrow biopsy should not be performed routinely; ITP diagnosis is clinical. [1][5]
• Reassess treatment decisions regularly as patient preferences and disease characteristics evolve. 11

Management Recommendations for Immune Thrombocytopenic Purpura (ITP)

Children – Initial Management

• Observation is preferred over intravenous immunoglobulin (IVIg) for children with newly diagnosed ITP who have no or only minor bleeding, reserving treatment for those with significant hemorrhage or impaired quality of life. 13

Adults – Therapeutic Sequencing

• Combining rituximab with corticosteroids as first‑line therapy is not recommended because current evidence does not demonstrate additional benefit. 13

• For patients with persistent ITP (3–12 months) who remain dependent on or unresponsive to corticosteroids, thrombopoietin‑receptor agonists (romiplostim or eltrombopag) should be used preferentially over rituximab. 13

Evidence‑Based Management of Immune Thrombocytopenia (ITP)

Diagnostic Evaluation

• All patients with newly diagnosed ITP should be screened for hepatitis C virus and human immunodeficiency virus to identify secondary causes. American Society of Hematology (ASH) recommendation. 14
• Systematic testing for Helicobacter pylori (urea‑breath test, stool antigen, or endoscopic biopsy) is advised, and eradication therapy should be given when infection is confirmed. ASH recommendation. 15
• A bone‑marrow examination is not required in patients with typical isolated thrombocytopenia, irrespective of age. ASH recommendation. 14
• Additional laboratory investigations are warranted only when abnormalities other than isolated thrombocytopenia are present (e.g., iron‑deficiency signs). ASH recommendation. 14

First‑Line Therapy in Adults

• For adults presenting with platelet counts < 30 × 10⁹/L, initiate a prolonged‑course corticosteroid regimen rather than a short‑course regimen. ASH recommendation (Grade 1B). 15
• Prednisone 0.5–2 mg/kg/day with a gradual taper is therapeutically equivalent to other corticosteroid options. ASH recommendation. 15
• Dexamethasone 40 mg daily for 4 days provides comparable efficacy to prednisone. ASH recommendation. 14
• Intravenous immunoglobulin (IVIG) should be added to corticosteroids when a rapid platelet rise is required (e.g., active bleeding or urgent surgery). Initial dose = 1 g/kg as a single infusion, repeatable if needed. ASH recommendation (Grade 1B). 15
• If corticosteroids are contraindicated, IVIG or anti‑D immunoglobulin (for Rh‑positive, non‑splenectomized patients) are appropriate alternatives. ASH recommendation. 14
• Critical pitfall: Do not combine rituximab with corticosteroids as first‑line therapy; ASH 2019 guidelines advise against this due to insufficient evidence of added benefit (Grade 2C). 16

Second‑Line Therapy (Corticosteroid Failure)

General Principles

• Choice of second‑line agent depends on disease duration (< 12 months vs ≥ 12 months) and patient priorities (avoidance of chronic medication, surgery, or desire for durable remission).

Disease Duration < 12 Months

• Thrombopoietin‑receptor agonists (TPO‑RA) (romiplostim or eltrombopag) are preferred over rituximab. ASH recommendation (Grade 1B). 16
• Splenectomy should be deferred during the first year because spontaneous remission remains possible. ASH recommendation (Grade 1B). 17

Disease Duration ≥ 12 Months

• Patients wishing to avoid long‑term medication: rituximab is favored over splenectomy despite lower durability, due to surgical risks. (no specific grade cited).
• Patients wishing to avoid surgery: TPO‑RA are favored over rituximab because of superior durability. ASH recommendation (Grade 1B). 16
• Patients seeking the most durable response: either splenectomy or TPO‑RA may be chosen, based on acceptance of surgery versus chronic therapy.

Formal ASH Recommendations

• Splenectomy is recommended for patients who fail corticosteroids (Grade 1B). 14
• TPO‑RA are recommended for patients at high hemorrhagic risk who relapse after splenectomy or have contraindications to splenectomy and have failed ≥ 1 other therapy (Grade 1B). 15
• Laparoscopic and open splenectomy provide comparable efficacy. ASH recommendation. 15
• Conditional use: TPO‑RA may be introduced earlier (after corticosteroids/IVIG) in hemorrhagic‑risk patients not yet splenectomized (Grade 2C). 14
• Conditional use: Rituximab may be considered for hemorrhagic‑risk patients after failure of one prior line (Grade 2C). 15

Post‑Splenectomy Management

• Asymptomatic patients with platelet counts > 30 × 10⁹/L should not receive additional treatment. ASH recommendation (Grade 1B). 14
• In the event of relapse after splenectomy, TPO‑RA are strongly recommended. ASH recommendation (Grade 1B). 15
• Up to 30 % of patients treated with TPO‑RA achieve long‑term remission after discontinuation of therapy. (observational data). 18

Special Populations

Pregnancy

• Pregnant patients requiring therapy should receive corticosteroids or IVIG. ASH recommendation (Grade 1B). 14
• Mode of delivery is determined by obstetric indications, not solely by platelet count. 15

Secondary ITP

• HIV‑associated ITP: Initiate antiretroviral therapy first (Grade 1A); if ITP treatment is needed, use corticosteroids, IVIG, or anti‑D. 15
• HCV‑associated ITP: Consider antiviral therapy while monitoring platelets (interferon may worsen thrombocytopenia); if ITP treatment is required, IVIG is the preferred first agent. 15
• H. pylori‑associated ITP: Provide eradication therapy to all patients with confirmed infection (Grade 1B). 14

Critical Pitfalls to Avoid

• Never perform routine bone‑marrow examination in typical ITP; diagnosis is clinical. ASH recommendation. 14
• Do not rush splenectomy within the first year of diagnosis, as spontaneous remission can occur. ASH recommendation. 17
• Avoid combining rituximab with corticosteroids as initial therapy due to lack of proven benefit. ASH recommendation (Grade 2C). 16
• Do not prolong corticosteroid therapy unnecessarily, as this raises bleeding risk and side‑effects such as weight gain, osteoporosis, cataracts, and infections. (Evidence level moderate). 17
• Long‑term risks of splenectomy include infections, thromboembolic events, possible malignancies, and a persistent excess mortality risk beyond 10 years post‑surgery. ASH recommendation. 19

First‑Line and Subsequent Management of Immune Thrombocytopenia (ITP)

First‑Line Therapy for Adults

• Initiate a prolonged course of corticosteroids (prednisone 0.5–2 mg/kg/day or dexamethasone 40 mg/day for 4 days) in newly diagnosed adults when platelet count is < 30 × 10⁹/L; add a single dose of IVIg 1 g/kg if a rapid platelet rise is required for active bleeding or urgent procedures. 20
• Longer corticosteroid courses are preferred over short courses or IVIg monotherapy for newly diagnosed ITP. [21][20]
• Prednisone and dexamethasone provide equivalent efficacy; selection should be based on side‑effect profile and patient tolerance. 20
• Therapy should be started when platelet count falls below 30 × 10⁹/L, or at a higher threshold if the patient has symptomatic bleeding. [21][20]
• Add IVIg (1 g/kg single dose) to corticosteroids when rapid platelet elevation is needed for active bleeding or urgent surgery. [21][20]
• IVIg may be repeated if the initial response is inadequate. 21
• If corticosteroids are contraindicated, use IVIg or anti‑D immunoglobulin (in Rh‑positive, non‑splenectomized patients without anemia or autoimmune hemolysis). 21
• Do not combine rituximab with corticosteroids as initial therapy; the American Society of Hematology (ASH) 2019 guidelines advise against this due to insufficient evidence of added benefit (Grade 2C). 20

Second‑Line Therapy After Corticosteroid Failure

Disease Duration < 12 Months

• Thrombopoietin‑receptor agonists (TPO‑RAs) such as romiplostim or eltrombopag are preferred over rituximab because they provide superior durability of response. 20
• Delay splenectomy during the first year because spontaneous remission occurs in up to one‑third of patients. [21][20]

Formal ASH Recommendations (Second‑Line)

Disease Duration ≥ 12 Months (Patient‑Centred Decision)

• For patients who wish to avoid long‑term medication, rituximab is preferred over splenectomy despite lower durability, because splenectomy carries lifelong infection risk, thromboembolic events, and excess mortality beyond 10 years. [no citation – omitted]
• For patients who wish to avoid surgery, TPO‑RAs are preferred over rituximab because of superior durability with ongoing use. 20
• For patients prioritising a durable response, either splenectomy or a TPO‑RA is acceptable; choice depends on willingness for surgery versus chronic medication. 20

Post‑Splenectomy Management

• Do not treat asymptomatic patients after splenectomy who have platelet counts > 30 × 10⁹/L. 21
• For relapse after splenectomy, TPO‑RAs are strongly recommended (Grade 1B). 21

Special Populations

Pregnancy

• Pregnant patients requiring ITP treatment should receive only corticosteroids or IVIg. 21
• Mode of delivery is determined by obstetric indications, not by platelet count alone. 21

Secondary ITP

• HCV‑associated ITP: If ITP‑directed therapy is needed, IVIg is the preferred first agent. 21
• H. pylori‑associated ITP: Provide eradication therapy to all patients with confirmed infection (Grade 1B) using urea breath test, stool antigen, or endoscopic biopsy for diagnosis. 21

Pediatric Patients

• Observation is preferred over treatment for children with no bleeding or only minor bleeding (e.g., skin manifestations), regardless of platelet count. [21][22]
• When treatment is required, use a single‑dose IVIg (0.8–1 g/kg) or a short‑course corticosteroid regimen as first‑line therapy. [21][22]
• Anti‑D (50–75 µg/kg) may be used in Rh‑positive, non‑splenectomized children without anemia or autoimmune hemolysis. 22
• Delay splenectomy for ≥ 12 months unless disease is severe and refractory to other measures. [21][22]

Critical Pitfalls to Avoid

• Never perform routine bone‑marrow examination in typical ITP; diagnosis is clinical exclusion of other causes. [21][22]
• Avoid combining rituximab with corticosteroids as initial therapy because of lack of proven benefit (Grade 2C). 20
• Do not prolong corticosteroid therapy unnecessarily, as this raises bleeding risk and side‑effects such as weight gain, osteoporosis, cataracts, and infections. [no citation – omitted]
• Monitor for thrombotic complications in patients on TPO‑RAs, especially those with persistent risk factors; consider long‑term anticoagulation in high‑risk patients. [no citation – omitted]

Diagnostic Workup Before Treatment

• Test all patients for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) to identify secondary causes (Grade 1B). 21
• Screen for H. pylori infection and provide eradication therapy when positive (Grade 1B). 21
• Additional investigations are warranted only when abnormalities extend beyond isolated thrombocytopenia (excluding iron‑deficiency findings). 21

IVIG Dosing and Safety Guidelines for Immune Thrombocytopenia and High‑Risk Patients

Dose Recommendations for Immune Thrombocytopenia (ITP)

• The recommended IVIG regimen for ITP is 0.4 g/kg per day for 1–2 days; this dosing is supported by multiple Blood 2010 guideline statements. 23, 24, 25, 26
• When a rapid platelet rise is needed, a single dose of 1 g/kg may be administered, providing the total amount in one infusion. 23, 24

Discontinuation Criteria

• IVIG therapy can be stopped after 1–2 days if an adequate platelet response has been achieved, avoiding unnecessary exposure. 23, 24

High‑Risk Patient Considerations

• Patients ≥ 65 years old, with pre‑existing renal insufficiency, volume depletion, sepsis, or receiving concurrent nephrotoxic drugs should receive the minimum effective dose and the slowest feasible infusion rate, with close monitoring of renal function before and after infusion. 27

Contraindications

• IgA deficiency with anti‑IgA antibodies and a prior history of hypersensitivity to immunoglobulin is an absolute contraindication to IVIG because the product contains trace IgA. 26

Black‑Box Warnings

• Thrombosis risk is increased in patients who are older, immobilized, have hypercoagulable states, indwelling catheters, or cardiovascular risk factors; clinicians must assess these factors before initiating IVIG. 28
• Acute renal failure is a recognized warning, particularly with sucrose‑containing IVIG formulations; sucrose‑free products mitigate but do not eliminate this risk. 28

Common Adverse Events and Management

• The most frequently reported infusion‑related adverse events are headache, flushing, fever, chills, fatigue, nausea, and blood‑pressure changes; these are observed across multiple studies. 23, 24, 26
• Premedication with acetaminophen or corticosteroids can reduce the incidence and severity of infusion reactions, as demonstrated in guideline‑based investigations. 23, 27

IVIG Use in Immune Thrombocytopenia (ITP) – ASH Guideline Recommendations

Indications for Adding IVIG to Corticosteroids

• Add a single‑dose IVIG (1 g/kg) to corticosteroids when rapid platelet elevation is essential, such as in patients with active bleeding, urgent surgery, or life‑threatening hemorrhage. 29
• Combine IVIG with corticosteroids for patients undergoing urgent invasive procedures. 30
• Use IVIG adjunctively whenever a faster platelet rise is required beyond what corticosteroids alone can provide. 31

IVIG Monotherapy When Steroids Are Contra‑indicated

• Employ IVIG alone (or anti‑D when appropriate) as first‑line therapy for ITP patients who cannot receive corticosteroids because of uncontrolled diabetes, active infection, severe psychiatric disease, or other absolute contraindications. 29
• In these situations, a single infusion of IVIG 1 g/kg is the recommended alternative. 31

Emergency Management of Life‑Threatening Bleeding

• For life‑, limb‑, or sight‑threatening bleeding (e.g., intracranial hemorrhage), initiate IVIG together with high‑dose corticosteroids immediately; IVIG provides the fastest onset of platelet recovery. 32
• Administer platelet transfusions every 30 minutes to 8 hours, preferably concurrently with continuous IVIG infusion, to support hemostasis. 33
• Recombinant factor VIIa may be considered as a rescue therapy; case series report cessation of bleeding but note a significant thrombosis risk (3 deaths among 18 reported cases). 32
• Emergent splenectomy is a last‑resort option, bearing high surgical risk and requiring careful peri‑operative planning. 33
• Antifibrinolytic agents (e.g., aminocaproic acid, tranexamic acid) have been described only in case reports and lack proven efficacy. 32

Special Populations

Pregnancy

• Pregnant patients with ITP should be treated with corticosteroids or IVIG; IVIG is especially valuable when steroids are poorly tolerated or contraindicated. 29

Viral‑Associated ITP

• In hepatitis‑C‑related ITP, IVIG is the preferred initial agent because corticosteroids may exacerbate viral replication. 31
• For HIV‑associated ITP, prioritize antiretroviral therapy; if additional ITP therapy is needed, corticosteroids, IVIG, or anti‑D are acceptable options. 31

Pediatric Patients

• Children with ITP who have no or only minor bleeding should be observed rather than treated, irrespective of platelet count. 34
• When treatment is indicated in children, IVIG 0.8–1 g/kg as a single dose is an acceptable first‑line option alongside short‑course corticosteroids. 30

Dosing and Administration

• The standard IVIG regimen for ITP is 1 g/kg given as a single infusion; the dose may be repeated if the initial response is inadequate. 29
• An alternative schedule of 0.4 g/kg per day for 1–2 days provides comparable efficacy but requires multiple infusions. 30

Safety, Adverse Events, and Contra‑indications

• Common infusion‑related reactions include headache, flushing, fever, chills, fatigue, nausea, and blood‑pressure changes; pre‑medication with acetaminophen or corticosteroids reduces their frequency and severity. 30
• Absolute contraindication: patients with IgA deficiency who have anti‑IgA antibodies and a prior hypersensitivity reaction to immunoglobulin. 30

Situations to Avoid IVIG

• Do not use IVIG as routine first‑line monotherapy in stable, non‑bleeding patients with newly diagnosed ITP; prolonged corticosteroid courses are preferred for cost‑effectiveness and sustained response. 29
• Do not combine rituximab with corticosteroids and IVIG as initial therapy; the 2019 ASH guidelines advise against this due to insufficient supporting evidence. 34
• Do not administer IVIG to asymptomatic post‑splenectomy patients whose platelet counts exceed 30 × 10⁹/L. 31
• Do not delay IVIG in life‑threatening bleeding while awaiting corticosteroid effect, as IVIG has the quickest onset of action. 32